Editorial
PLX51107, a promising novel bromodomain and extra-terminal inhibitor in chronic lymphoid leukemia treatment
Abstract
Historically hematopoietic malignancies were classified as genetic diseases depending on a small number of driver mutations. Nevertheless, the exact molecular mechanisms driving disease development of malignancies such as chronic lymphoid leukemia (CLL) still remain elusive in most part.
